Whole Coffee Fruit Concentrate Pilot Study 1
NCT01965795 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39
Last updated 2015-01-19
Summary
The purpose of this pilot study is to evaluate the potential effects of whole coffee fruit concentrate (WCFC, Neurofactor), a product that elevates circulating brain-derived neurotrophic factor (BDNF), on cognition and mood in healthy adults.
The projected outcome of this study is that self-administration of Neurofactor for 28 days (or even 14 days) will be associated with an improvement in mood and scores on cognitive tests, and that the change will exceed that observed with administration of Nutrim (placebo).
Volunteers will be recruited from the greater Los Angeles community. Participants will be middle-aged nonsmokers, in good health, and between the ages of 40-55 to enhance the chance of demonstrating pro-cognitive effects. Younger participants, whose cognitive performance is expected to be higher, may perform at a ceiling level, with less room for improvement by the product under study.
Participants who call our lab will be told about the study in more detail, and will complete a 5 minute phone screener to determine preliminary eligibility. After the initial telephone screening, participants will visit Dr. London's laboratory at UCLA to provide written informed consent.
The first study visit will be an in-person screening visit to determine full eligibility. The evaluation will include a psychiatric diagnostic interview, using the SCID, blood tests, urine samples (to test for drug use and pregnancy). Participants will also be interviewed about their prior and current drug use, including tobacco use. In addition, participants will be interviewed about the nature of their employment and physical exercise habits: endurance training has been shown to increase plasma BDNF in young men.
Participants meeting the inclusion criteria will attend the Semel Institute for Neuroscience and Human Behavior at UCLA to take part in baseline measurements, and to be randomized to receive either WCFC or placebo. During the active treatment time (28 days), they will visit the UCLA Semel Institute on a weekly basis. At each of these weekly visits, questionnaires regarding compliance will be completed, and blood samples will be taken for assay of BDNF. A cognitive test battery and mood-rating scales will be completed at baseline and at 14 and 28 days of treatment. At the midpoint assessment (14 days) and at completion of treatment (28 days) blood will be drawn for assay of a blood chemistry panel (as at baseline) as well as for biomarkers in addition to BDNF.
Conditions
- Brain-derived Neurotrophic Factor (BDNF)
- Cognitive Function
- Affect
Interventions
- DIETARY_SUPPLEMENT
-
Whole Coffee Fruit Concentrate (WCFC)
Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain-Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
- DIETARY_SUPPLEMENT
-
Nutrim
Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
Sponsors & Collaborators
-
Applied BioClinical Inc.
collaborator INDUSTRY -
University of California, Los Angeles
lead OTHER
Principal Investigators
-
Edythe D London, PhD · Professor in Residence
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2014-12-31
- Completion
- 2014-12-31
Countries
- United States
Study Locations
More Related Trials
-
The Role of Short Chain Fatty Acids in Microbiota-gut-brain Axis
NCT03688854 ·Status: COMPLETED ·Phase: NA
-
The Cognitive Effects of 6- and 12-weeks Administration of a Food Supplement Containing Phosphatidylserine in Healthy Children Aged 8 to 12 Years
NCT05177978 ·Status: COMPLETED ·Phase: NA
-
Investigating the Effects of Dietary Phospholipids on Measures of Human Brain Health and Psychological Wellbeing
NCT06107075 ·Status: RECRUITING ·Phase: NA
-
Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline
NCT01746303 ·Status: COMPLETED ·Phase: NA
-
Fatty Acid Supplementation in Children With ASD
NCT03550209 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function
NCT00662142 ·Status: COMPLETED ·Phase: PHASE3
-
Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy
NCT00299533 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Long-Chain Polyunsaturated Fatty Acids on Cognitive Performance and Mood
NCT00615277 ·Status: COMPLETED ·Phase: NA
-
Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition
NCT00982462 ·Status: COMPLETED ·Phase: NA
-
Fatty Acids and Executive Function Development in 7-12 Year Olds
NCT02199808 ·Status: COMPLETED
-
Effect of Fish Oil on Athlete's Executive Function
NCT04570995 ·Status: TERMINATED ·Phase: NA
-
Fatty Acid Supplementation in Children With ASD (Study 2)
NCT04312932 ·Status: COMPLETED ·Phase: PHASE2
-
Essential Fatty Acid Nutrition For 1-2 Yr-Olds
NCT01263912 ·Status: COMPLETED ·Phase: NA
-
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions
NCT01814527 ·Status: COMPLETED ·Phase: NA
-
Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults
NCT02626247 ·Status: UNKNOWN ·Phase: NA
-
Effects of Polyunsaturated Fatty Acids on the Visual Memory of Children With Attention Deficit Hyperactivity Disorder
NCT03299647 ·Status: UNKNOWN
-
Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers
NCT01391624 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
NCT01515917 ·Status: WITHDRAWN ·Phase: NA
-
Omega-3 Unsaturated Fatty Acid Improves Cognitive Function in Patients With Depression
NCT04803071 ·Status: UNKNOWN ·Phase: NA
-
Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition
NCT01199120 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders
NCT01769092 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Enhancing Children's Cognitive Function and Achievement Through Carotenoid Consumption
NCT05177679 ·Status: RECRUITING ·Phase: NA
-
Effects of Docosahexaenoic Acid (DHA)-Rich Fish Oil on Cerebral Haemodynamics
NCT01075932 ·Status: COMPLETED ·Phase: NA
-
Walnuts, Long-Chain Polyunsaturated Fatty Acids and Adolescent Brain Development
NCT02590848 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Treatment for Concussion in Adolescents
NCT05847608 ·Status: UNKNOWN ·Phase: NA